NCT06067828进行中（未招募）3 期
A Double-Blind, Multicentre, Randomized, Three-Period, Three-Treatment, Cross-Over Study to Evaluate the Effect of BGF MDI, BFF MDI, and Placebo MDI on Exercise Parameters in Participants With COPD (ATHLOS)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- AstraZeneca
- 入组人数
- 171
- 试验地点
- 34
- 主要终点
- Change from baseline in isotime Inspiratory capacity (IC)
研究概览
简要总结
This study will investigate the effect of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) compared with Placebo MDI, and Budesonide and Formoterol Fumarate (BFF) MDI on isotime inspiratory capacity (IC) and exercise endurance time.
详细描述
This is a multicenter, three-treatment, three-period, cross-over study to assess the effect of BGF MDI vs Placebo MDI and BFF MDI in participants with COPD who have exertional breathlessness despite treatment with mono or dual COPD maintenance therapy.
Eligible participants will be randomized equally (1:1:1:1:1:1) to 1 of 6 treatment sequences. The total duration of the study for each participant will be up to 14 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be male or female, 40 to 80 years of age inclusive, at the time of signing the informed consent.
- •Participant must have:
- •a diagnosis of COPD confirmed by a post-bronchodilator Forced expiratory volume (FEV1)/ Forced vital capacity (FVC) < 0.7 at Visit 1
- •a post-bronchodilator FEV1 ≥ 30% and <80% predicted normal (moderate to severe COPD) at Visit
- •a score of ≥ 2 on the modified Medical Research Council at Visit
- •pre-bronchodilator FRC of > 120% of predicted normal FRC values at Visit
- •a constant work rate test endurance time of 3 to 8 minutes at Visit
- •Participant must be on a stable dose of mono-or dual inhaled maintenance COPD treatment for at least 6 weeks.
- •Current or former smoker with a history of ≥ 10 pack-years of tobacco smoking
- •Body mass index < 40 kg/m
- •Male and Female participants (not applicable for female participants with non-childbearing potential) and their partners must use an acceptable method of contraception.
排除标准
- •A current diagnosis of asthma, asthma- COPD-overlap, or any other chronic respiratory disease other than COPD such as alpha-1 antitrypsin deficiency, active tuberculosis, lung cancer, lung fibrosis, sarcoidosis, interstitial lung disease and pulmonary hypertension.
- •Historical or current evidence of a clinically significant disease
- •Participants on oxygen therapy or that desaturate significantly (<82%) during exercise.
- •Participants who are enrolled or entering a pulmonary rehabilitation program during the study.
- •Participants who have cancer that has not been in complete remission for at least 5 years.
- •Participants with a diagnosis of narrow-angle glaucoma that has not been adequately treated and/or change in vision that may be relevant, in the opinion of the investigator.
- •Participants with symptomatic prostatic hypertrophy or bladder neck obstruction/urinary retention that, in the opinion of the investigator, is clinically significant.
- •Participants who have a history of hypersensitivity to β2-agonists, budesonide or any other corticosteroid components, glycopyrronium or other muscarinic anticholinergics, or any component of the MDI or dry powder inhaler.
- •Participant with resting (5 minutes) oxygen saturation SaO2 in room air ≤ 85%.
- •A COPD exacerbation that requires hospitalization within 12 months prior to Visit 1 or a COPD exacerbation that requires systemic corticosteroids or antibiotics within 4 months of Visit
- •Participants with contraindications to cardiopulmonary exercise testing (CPET).
- •Participants who have had a respiratory tract infection within 8 weeks prior to Visit 1 and/or during the screening period.
- •Participants with lung lobectomy, lung volume reduction or lung transplantation.
- •Unable to withhold short-acting bronchodilators for 6 hours prior to lung function testing at each study visit.
- •Known history of drug or alcohol abuse within 12 months.
- •Any regular recreational use of marijuana in the 12 months.
结局指标
主要结局
Change from baseline in isotime Inspiratory capacity (IC)
时间窗: 2 weeks post-treatment
To assess the effect of BGF MDI relative to Placebo MDI and BGF MDI relative to BFF MDI on dynamic hyperinflation in participants with COPD.
次要结局
- Change from baseline in static Inspiratory capacity (IC)(2 weeks post-treatment)
- Change from baseline in residual volume (RV)(2 weeks post-treatment)
- Change from baseline in Isotime dyspnea (NRS)(2 weeks post-treatment)
- Change from baseline in RV/TLC(2 weeks post-treatment)
- Change from baseline in specific airway conductance (sGaw)(2 weeks post-treatment)
- Change from baseline in constant work rate cycle ergometry endurance time(2 weeks post-treatment)
- Number of participants with serious adverse events (SAEs) and adverse event leading to discontinuation of study intervention (DAEs).(2 weeks post-treatment)
- Change from baseline in functional residual capacity (FRC)(2 weeks post-treatment)
- Change from baseline in total lung capacity (TLC)(2 weeks post-treatment)
研究者
研究点 (34)
Loading locations...
相似试验
撤回
1 期
A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a SpacerHealthyNCT06340581AstraZeneca132
已完成
不适用
Study on the effects of the budesonide/formoterol combination formulation in improving airway inflammation and airway resistance in patients with bronchial asthmaPatients with bronchial asthma aged 20 years and older (males and females, outpatients and inpatients) being treated with an ICS (at a dose equivalent to FP 200-1000 mcg/day) and salmeterol 100 mcg/day in combination (either as two separate products or one combined product) for 3 months or longer with poor or inadequate controlJPRN-UMIN000006572Chiba-Hokusoh Hospital, Nippon Medical School80
已完成
3 期
Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)Oral Chronic Graft vs Host DiseaseNCT00887263Dr. Falk Pharma GmbH186
已完成
3 期
Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down AsthmaAsthmaNCT02725242Hat Yai Medical Education Center77
已完成
3 期
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)AsthmaNCT05202262AstraZeneca645